Prostate Cancer
Clinical Trials

1) First Line Metastatic mCRPC: USO #19191: BMS CA209-7DX: A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (Check-Mate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)

2) Cohort 21 and 23 part of XL184-021 EXELIXIS: A Phase Ib Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (More information under Prostate Cancer/Solid Tumors Section)

Send UsA Message

    Staying Aware for Breast Cancer Awareness Month

    Staying Aware for Breast Cancer Awareness Month

    Staying Aware for Breast Cancer Awareness monthCharleston Oncology is proud to sponsor Staying Aware for Breast Cancer Awareness month in conjunction with WCIV News Channel 4. We continue to partner with our community to ensure that every woman has the best chance of...

    read more
    Game Changing Neoadjuvant Lung Trial Enrolls the Most People in the World

    Game Changing Neoadjuvant Lung Trial Enrolls the Most People in the World

    Charleston Oncology’s Clinical Trials most recent non–small cell lung cancer trial enrolled the most people in the world. Gene Saylors, MD, oncologist and hematologist at Charleston Oncology, will present the positive findings at the American Association for Cancer Research 2022 Annual Meeting. “When administering a new trial, we are always cautiously optimistic,” says Dr. Gene Saylors. “The positive results of this Neoadjuvant Lung Trial resulted in rapid FDA approval due to its impressive outcomes.”

    read more
    Call Now Button